Sutro Biopharma (STRO) AI Stock Analysis

• Market Cap: $393.97M
• Dividend Yield: N/A
• Average Volume (3M): 987.85K
• Price to Earnings (P/E): ―
• Beta (1Y): 3.47
• Revenue Growth: -34.36%
• EPS Growth: -59.98%
• Country: US
• Employees: 269
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -5.29
• Shares Outstanding: 16,567,238
• 10 Day Avg. Volume: 2,002,360
• 30 Day Avg. Volume: 987,852
• PEG Ratio: 0.02
• Price to Book (P/B): -0.74
• Price to Sales (P/S): 0.96
• P/FCF Ratio: -0.55
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: 3.71
• Enterprise Value/Gross Profit: 3.77
• Enterprise Value/Ebitda: -3.14
• 1Y Price Target: $27.17
• Price Target Upside: 14.26% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -9.95
• Revenue Forecast (FY): $35.00M

• Rating: 51 Neutral
• Price Target: $21.50 ▼(-9.59% Downside)
• Action: Reiterated Date: 03/24/26
• Date: Action: Reiterated 03/24/26

Overall score reflects high financial risk (persistent losses, cash burn, and negative equity) as the primary drag. Technicals are moderately supportive with price above key longer-term moving averages, while valuation provides limited support due to negative earnings and no dividend. Corporate events modestly improve the outlook by extending cash runway and highlighting pipeline progress.

Positive Factors

Proprietary cell-free platform

Sutro’s XpressCF cell-free platform is a durable competitive asset: it enables rapid, precise protein engineering and production, accelerates discovery and scale-up, supports both internal ADC programs and partner collaborations, and underpins recurring technology licensing and services revenue potential.

Negative Factors

Negative stockholders' equity

Equity erosion to a negative position is a durable balance-sheet red flag: it reduces financial flexibility, can impair borrowing capacity, weakens the company’s capital structure, and increases dependence on dilutive financings or partner funding to sustain R&D and clinical plans.

Sutro Biopharma Business Overview & Revenue Model

Company Description

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specif...

Read more

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specif...

How the Company Makes Money

Sutro primarily generates revenue through collaboration and licensing arrangements rather than product sales, because it is a clinical-stage company and does not have null. Key revenue streams generally include (1) upfront payments received when e...

Read more

Sutro primarily generates revenue through collaboration and licensing arrangements rather than product sales, because it is a clinical-stage company and does not have null. Key revenue streams generally include (1) upfront payments received when e...

Sutro Biopharma Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	102.48M	62.04M	153.73M	67.77M	61.88M
Gross Profit	95.16M	54.83M	146.91M	59.48M	52.11M
EBITDA	-97.63M	-180.45M	-67.92M	-105.07M	-97.56M
Net Income	-191.09M	-227.46M	-106.79M	-119.20M	-105.54M
Balance Sheet
Total Assets	173.83M	387.21M	470.74M	406.94M	341.41M
Cash, Cash Equivalents and Short-Term Investments	141.43M	316.89M	375.62M	334.36M	197.94M
Total Debt	15.67M	23.15M	33.63M	55.02M	57.37M
Total Liabilities	306.28M	342.61M	321.09M	189.90M	88.84M
Stockholders Equity	-132.45M	44.60M	149.65M	217.05M	252.56M
Cash Flow
Free Cash Flow	-178.93M	-194.64M	-115.93M	-4.31M	-97.00M
Operating Cash Flow	-177.23M	-191.54M	-111.62M	3.55M	-81.68M
Investing Cash Flow	45.01M	218.51M	-3.92M	-35.02M	-97.31M
Financing Cash Flow	44.00K	94.05M	137.55M	48.31M	3.26M

Sutro Biopharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 23.78
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STRO, the sentiment is Positive. The current price of 23.78 is above the 20-day moving average (MA) of 23.66, above the 50-day MA of 19.79, and above the 200-day MA of 11.87, indicating a bullish trend. The MACD of 1.26 indicates Positive momentum. The RSI at 57.22 is Neutral, neither overbought nor oversold. The STOCH value of 74.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STRO.

Sutro Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
STRO	51 Neutral	$393.97M	-0.51	861.99%	―	-34.36%	-59.98%
CRVO	47 Neutral	$38.33M	-2.65	-96.04%	―	-38.81%	-76.96%
INMB	46 Neutral	$32.17M	-0.90	-171.01%	―	19.05%	2.01%
ACET	45 Neutral	$67.08M	-0.50	-82.96%	―	―	25.89%
HOWL	45 Neutral	$49.08M	-0.48	-122.43%	―	-100.00%	-8.30%

Sutro Biopharma Corporate Events